The 20 top-selling vaccines in H1 2012

Tools

Data on the biggest-selling vaccines helps us understand what's driving growth in the vaccines industry, and which companies are behind the wheel. Thanks in part to the adult influenza market and vaccines such as Gardasil and Prevnar, the global vaccines market has enjoyed a decidedly solid boost in revenue. Ten years ago, the vaccine market sat at $5.7 billion dollars, according to Kalorama Information. Now, that market has soared to $27 billion.

Much of the growth comes as a result of a focus on flu prevention and an acceptance of adult vaccines. A few new vaccines joining the roster help, too. Sales of adult vaccines are expected to increase at a compound annual rate of 10.3% from 2010 to 2015, Kalorama reports.

As H1 came to a close, FierceVaccines decided to take a look at which prophylactic vaccines flew off the shelves--and which companies made the sales. 

Big Pharma products predictably dominated the list. Merck ($MRK) and GlaxoSmithKline ($GSK) take the cake when it comes to selling vaccines; each had 6 vaccines in the top 20 sales. Yet Sanofi ($SNY) and Pfizer ($PFE) had multiple products, too. And Novartis ($NVS) and Emergent BioSolutions each made an appearance.

With information provided by EvaluatePharma, the list is in. Take a look at the full list >> Alison Bryant  (email | Twitter)